Selenoproteins in bladder cancer

Clinica Chimica Acta

Volumn 413, Issue 9-10, 2012, Pages 847-854

  Reszka, Edyta ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Bladder cancer; Glutathione peroxidase; Selenium; Selenoproteins; Thioredoxin reductase

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; GLUTATHIONE PEROXIDASE; MESSENGER RNA; PLACEBO; SELENIUM; SELENIUM BINDING PROTEIN; SELENOPROTEIN; SELENOPROTEIN T; SELENOPROTEIN W; THIOREDOXIN REDUCTASE 1; THYROXINE DEIODINASE; TRACE ELEMENT; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER PATIENT; CANCER RISK; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; REVIEW; RISK FACTOR; RISK REDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, MESSENGER; SELENOPROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

ANIMALIA; MAMMALIA;

EID: 84858624566     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.041     Document Type: Review

References (89)

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27:289-293.
2. Cheng L., Zhang S., MacLennan G.T., Williamson S.R., Lopez-Beltran A., Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011, 42:455-481.
3. Cohen S.M. Urinary bladder carcinogenesis. Toxicol Pathol 1998, 26:121-127.
4. Grotenhuis A.J., Vermeulen S.H., Kiemeney L.A. Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol 2010, 6:1433-1460.
5. Volanis D., Kadiyska T., Galanis A., Delakas D., Logotheti S., Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 2010, 193:131-137.
6. Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306:737-745.
7. Amaral A.F., Cantor K.P., Silverman D.T., Malats N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010, 19:2407-2415.
8. Dennert G., Zwahlen M., Brinkman M., Vinceti M., Zeegers M.P., Horneber M. Selenium for preventing cancer. Cochrane Database Syst Rev 2011, 5:CD005195.
9. Michaud D.S., De Vivo I., Morris J.S., Giovannucci E. Toenail selenium concentrations and bladder cancer risk in women and men. Br J Cancer 2005, 93:804-806.
10. Michaud D.S., Hartman T.J., Taylor P.R., et al. No association between toenail selenium levels and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1505-1506.
11. Nomura A., Heilbrun L.K., Morris J.S., Stemmermann G.N. Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data. J Natl Cancer Inst 1987, 79:103-108.
12. Duffield-Lillico A.J., Reid M.E., Turnbull B.W., et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002, 11:630-639.
13. Méplan C. Trace elements and ageing, a genomic perspective using selenium as an example. J Trace Elem Med Biol 2011, 25(Suppl. 1):S11-S16.
14. Akbaraly N.T., Arnaud J., Hininger-Favier I., Gourlet V., Roussel A.M., Berr C. Selenium and mortality in the elderly: results from the EVA study. Clin Chem 2005, 51:2117-2123.
15. Papp L.V., Lu J., Holmgren A., Khanna K.K. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 2007, 9:775-806.
16. Kobayashi Y., Ogra Y., Ishiwata K., Takayama H., Aimi N., Suzuki K.T. Selenosugars are key and urinary metabolites for selenium excretion within the required to low-toxic range. Proc Natl Acad Sci USA 2002, 99:15932-15936.
17. Hatfield D.L., Gladyshev V.N. How selenium has altered our understanding of the genetic code. Mol Cell Biol 2002, 22:3565-3576.
18. Hesketh J.E., Villette S. Intracellular trafficking of micronutrients: from gene regulation to nutrient requirements. Proc Nutr Soc 2002, 61:405-414.
19. Jameson R.R., Diamond A.M. A regulatory role for Sec tRNA[Ser]Sec in selenoprotein synthesis. RNA 2004, 10:1142-1152.
20. Schomburg L., Schweizer U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim Biophys Acta 2009, 1790:1453-1462.
21. Small-Howard A.L., Berry M.J. Unique features of selenocysteine incorporation function within the context of general eukaryotic translational processes. Biochem Soc Trans 2005, 33:1493-1497.
22. Gromadzinska J., Reszka E., Bruzelius K., Wasowicz W., Akesson B. Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur J Nutr 2008, 47(Suppl. 2):S29-S50.
23. Hawkes W.C., Alkan Z. Regulation of redox signaling by selenoproteins. Biol Trace Elem Res 2010, 134:235-251.
24. Shchedrina V.A., Zhang Y., Labunskyy V.M., Hatfield D.L., Gladyshev V.N. Structure-function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid Redox Signal 2010, 12:839-849.
25. Reeves M.A., Hoffmann P.R. The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci 2009, 66:2457-2478.
26. Sunde R.A. Molecular biomarker panels for assessment of selenium status in rats. Exp Biol Med 2010, 235:1046-1052.
27. McCann J.C., Ames B.N. Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging. FASEB J 2011, 25:1793-1814.
28. Fairweather-Tait S.J., Collings R., Hurst R. Selenium bioavailability: current knowledge and future research requirements. Am J Clin Nutr 2010, 91:1484S-1491S.
29. Burk R.F., Hill K.E. Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta 2009, 1790:1441-1447.
30. Yoo M.H., Carlson B.A., Tsuji P., Irons R., Gladyshev V.N., Hatfield D.L. Alteration of thioredoxin reductase 1 levels in elucidating cancer etiology. Methods Enzymol 2010, 474:255-275.
31. Jeong D., Kim T.S., Chung Y.W., Lee B.J., Kim I.Y. Selenoprotein W is a glutathione-dependent antioxidant in vivo. FEBS Lett 2002, 517:225-228.
32. Staack A., Hayward S.W., Baskin L.S., Cunha G.R. Molecular, cellular and developmental biology of urothelium as a basis of bladder regeneration. Differentiation 2005, 73:121-133.
33. Crallan R.A., Georgopoulos N.T., Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis 2006, 27:374-381.
34. Grimmer G., Dettbarn G., Seidel A., Jacob J. Detection of carcinogenic aromatic amines in the urine of non-smokers. Sci Total Environ 2000, 247:81-90.
35. Pavanello S., Simioli P., Mastrangelo G., et al. Role of metabolic polymorphisms NAT2 and CYP1A2 on urinary mutagenicity after pan-fried hamburger meal. Food Chem Toxicol 2002, 40:1139-1144.
36. Vineis P., Talaska G., Malaveille C., et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 1996, 65:314-316.
37. Soini Y., Haapasaari K.M., Vaarala M.H., Turpeenniemi-Hujanen T., Kärjä V., Karihtala P. 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. Int J Clin Exp Pathol 2011, 4:267-275.
38. Kuehnelt D., Kienzl N., Traar P., Le N.H., Francesconi K.A., Ochi T. Selenium metabolites in human urine after ingestion of selenite, l-selenomethionine, or dl-selenomethionine: a quantitative case study by HPLC/ICPMS. Anal Bioanal Chem 2005, 383:235-246.
39. Suzuki K.T., Somekawa L., Suzuki N. Distribution and reuse of 76Se-selenosugar in selenium-deficient rats. Toxicol Appl Pharmacol 2006, 216:303-308.
40. Poerschke R.L., Franklin M.R., Moos P.J. Modulation of redox status in human lung cell lines by organoselenocompounds: selenazolidines, selenomethionine, and methylseleninic acid. Toxicol In Vitro 2008, 22:1761-1767.
41. Swede H., Dong Y., Reid M., Marshall J., Ip C. Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture. Cancer Epidemiol Biomarkers Prev 2003, 12:1248-1252.
42. Halliwell B., Clement M.V., Long L.H. Hydrogen peroxide in the human body. FEBS Lett 2000, 486:10-13.
43. Borawska M.H., Socha K., Lazarczyk B., Czyzewska E., Markiewicz R., Darewicz B. The effects of diet on selenium concentration in serum in patients with cancer. Nutr Cancer 2009, 61:629-633.
44. Lin C.N., Wang L.H., Shen K.H. Determining urinary trace elements (Cu, Zn, Pb, As, and Se) in patients with bladder cancer. J Clin Lab Anal 2009, 23:192-195.
45. Ardanaz N., Pagano P.J. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006, 231:237-251.
46. Day R.M., Suzuki Y.J. Cell proliferation, reactive oxygen and cellular glutathione. Dose Response 2006, 3:425-442.
47. Stone J.R., Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006, 8:243-270.
48. Brigelius-Flohé R., Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009, 1790:1555-1568.
49. Hatfield D.L., Yoo M.H., Carlson B.A., Gladyshev V.N. Selenoproteins that function in cancer prevention and promotion. Biochim Biophys Acta 2009, 1790:1541-1545.
50. Hempel N., Ye H., Abessi B., Mian B., Melendez J.A. Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic Biol Med 2009, 46:42-50.
51. Baek I.J., Yon J.M., Lee S.R., et al. Differential expression of gastrointestinal glutathione peroxidase (GI-GPx) gene during mouse organogenesis. Anat Histol Embryol 2011, 40:210-218.
52. Lee S.R., Yon J.M., Baek I.J., et al. Spatiotemporal expression of the selenoprotein P gene in postimplantational mouse embryos. Int J Dev Biol 2008, 52:1005-1011.
53. Mohandas J., Marshall J.J., Duggin G.G., Horvath J.S., Tiller D.J. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res 1984, 44:5086-5091.
54. Zhang J., Ma K., Wang H. Cyclophosphamide suppresses thioredoxin reductase in bladder tissue and its adaptive response via inductions of thioredoxin reductase and glutathione peroxidase. Chem Biol Interact 2006, 162:24-30.
55. Singh S.V., Ahmad H., Krishan A. Expression of glutathione-related enzymes in human bladder cancer cell lines. Biochem Pharmacol 1990, 39:1817-1820.
56. Singh S.V., Xu B.H., Tkalcevic G.T., Gupta V., Roberts B., Ruiz P. Glutathione-linked detoxification pathway in normal and malignant human bladder tissue. Cancer Lett 1994, 77:15-24.
57. Wang X., Zhang J., Xu T. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur J Pharmacol 2008, 579:66-73.
58. Sanchez-Carbayo M., Socci N.D., Lozano J.J., et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003, 163:505-516.
59. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789.
60. Gerhard D.S., Wagner L., Feingold E.A., et al. MGC Project Team, The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res 2004, 14:2121-2127.
61. Yalçin O., Karataş F., Erulaş F.A., Ozdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004, 93:863-866.
62. Arikan S., Akcay T., Konukoglu D., Obek C., Kural A.R. The relationship between antioxidant enzymes and bladder cancer. Neoplasma 2005, 52:314-317.
63. Badjatia N., Satyam A., Singh P., Seth A., Sharma A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 2010, 28:360-367.
64. Reszka E., Gromadzinska J., Jablonska E., Wasowicz W., Jablonowski Z., Sosnowski M. Level of selenoprotein transcripts in peripheral leukocytes of patients with bladder cancer and healthy individuals. Clin Chem Lab Med 2009, 47:1125-1132.
65. Gauchez A.S., Riondel J., Jacrot M., Calop J., Favier A. Antioxidant status and lipid peroxidation in athymic mice xenografted with two types of human tumors. Biol Trace Elem Res 1995, 47:103-109.
66. Bayraktar N., Kilic S., Bayraktar M.R., Aksoy N. Lipid peroxidation and antioxidant enzyme activities in cancerous bladder tissue and their relation with bacterial infection: a controlled clinical study. J Clin Lab Anal 2010, 24:25-30.
67. Pendyala L., Velagapudi S., Toth K., et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997, 3:793-798.
68. Savic-Radojevic A., Mimic-Oka J., Pljesa-Ercegovac M., et al. Glutathione S-transferase-P1 expression correlates with increased antioxidant capacity in transitional cell carcinoma of the urinary bladder. Eur Urol 2007, 52:470-477.
69. Tan M., Li S., Swaroop M., Guan K., Oberley L.W., Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 1999, 274:12061-12066.
70. Krieg A.J., Hammond E.M., Giaccia A.J. Functional analysis of p53 binding under differential stresses. Mol Cell Biol 2006, 26:7030-7045.
71. Irons R., Tsuji P.A., Carlson B.A., et al. Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev Res (Phila) 2010, 3:630-639.
72. Jiang C., Hu H., Malewicz B., Wang Z., Lü J. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 2004, 3:877-884.
73. Hawkes W.C., Alkan Z. Delayed cell cycle progression from SEPW1 depletion is p53- and p21-dependent in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2011, 413:36-40.
74. Hawkes W.C., Printsev I., Alkan Z. Selenoprotein W depletion induces a p53- and p21-dependent delay in cell cycle progression in RWPE-1 prostate epithelial cells. J Cell Biochem 2011, [Epub ahead of print]. 10.1002/jcb.23328.
75. Sengupta A., Carlson B.A., Labunskyy V.M., Gladyshev V.N., Hatfield D.L. Selenoprotein T deficiency alters cell adhesion and elevates selenoprotein W expression in murine fibroblast cells. Biochem Cell Biol 2009, 87:953-961.
76. Brigelius-Flohé R., Banning A. Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free Radic Res 2006, 40:775-787.
77. Shan Y., Wang X., Wang W., He C., Bao Y. p38 MAPK plays a distinct role in sulforaphane-induced up-regulation of ARE-dependent enzymes and down-regulation of COX-2 in human bladder cancer cells. Oncol Rep 2010, 23:1133-1138.
78. Kawakami K., Enokida H., Tachiwada T., et al. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep 2006, 16:521-531.
79. Jiang T., Huang Z., Chan J.Y., Zhang D.D. Nrf2 protects against As(III)-induced damage in mouse liver and bladder. Toxicol Appl Pharmacol 2009, 240:8-14.
80. Iida K., Itoh K., Kumagai Y., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004, 64:6424-6431.
81. Iida K., Itoh K., Maher J.M., et al. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis 2007, 28:2398-2403.
82. Hu Y.J., Diamond A.M. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 2003, 63:3347-3351.
83. Jablonska E., Gromadzinska J., Reszka E., et al. Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur J Nutr 2009, 48:383-386.
84. Ichimura Y., Habuchi T., Tsuchiya N., et al. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 2004, 172:728-732.
85. Paz-y-Miño C., Muñoz M.J., López-Cortés A., et al. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer. Oncol Res 2010, 18:395-400.
86. Kucukgergin C., Sanli O., Amasyali A.S., Tefik T., Seckin S. Genetic variants of MnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population. Med Oncol 2011, 10.1007/s12032-011-0057-z.
87. Chiong E., Kesavan A., Mahendran R., et al. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 2011, 59:430-437.
88. Goerlitz D., El Daly M., Abdel-Hamid M., et al. GSTM1, GSTT1 null variants, and GPX1 single nucleotide polymorphism are not associated with bladder cancer risk in Egypt. Cancer Epidemiol Biomarkers Prev 2011, 20:1552-1554.
89. Zhao H., Liang D., Grossman H.B., Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 2005, 66:769-774.